Filana Therapeutics, Inc.
FLNA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001069530
No open-market purchases or sales by Filana Therapeutics, Inc. insiders were filed in the last 90 days; 85 institutions reported holding it in 13F filings for Q2 2026, worth $15.1M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Filana Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Filana Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Anderson Robert Eugene Jr | Director | 8,600 | Nov 25, 2025 | 1 |
| Barry Richard | President & CEO | 938,060Indirect | Nov 24, 2025 | 2 |
| Bir Dawn Carter | Director | – | Oct 22, 2025 | 1 |
| Cook Robert Christopher | Chief Operating & Legal Office | 13,725 | Oct 2, 2025 | 1 |
| Scannon Patrick J MD PhD | Director | 1,000 | Jul 16, 2025 | 0 |
| Gussin Robert Z | Director | 10,617 | May 27, 2025 | 0 |
| O Donnell Michael J | Director | 6,873 | May 27, 2025 | 0 |
| Nicaise Claude | Director | – | May 27, 2025 | 0 |
| Gravier Pierre | Director | – | May 27, 2025 | 0 |
| Schoen Eric | Chief Financial Officer | 11,500 | Apr 21, 2025 | 0 |
| Nassif Freda | Chief Business Officer | – | Apr 21, 2025 | 0 |
| Kupiec James William | Chief Medical Officer | 0 | Dec 3, 2024 | 0 |
| Landen Jaren | Chief Clinical Dev. Officer | – | Nov 20, 2024 | 0 |
| Barbier Remi | President & CEO | 734,279 | May 22, 2024 | 0 |
| Robertson Sanford | Director | 5,000Indirect | May 16, 2024 | 0 |
| Friedmann Nadav | Chief Medical Officer | 79,910 | Oct 3, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 25, 2025 (view filing) | Nov 24 | 1 day | Anderson Robert Eugene JrDirector | PPurchase | +8.60K | $2.90 | +$24.9K | New position8.60K after | |
| Nov 24, 2025 (view filing) | Nov 20 | 4 days | Barry RichardPresident & CEO | PPurchase | +150.0K | $2.76 | +$414.0K | +19.0%938.1K after | |
| Nov 20, 2025 (view filing) | Nov 19 | 1 day | Barry RichardPresident & CEO | PPurchase | +73.4K | $2.75 | +$201.8K | +10.3%788.1K after | |
| Oct 2, 2025 (view filing) | Sep 30 | 2 days | Cook Robert ChristopherChief Operating & Legal Office | PPurchase | +13.7K | $2.91 | +$39.9K | New position13.7K after | |
| Sep 23, 2025 (view filing) | Sep 22 | 1 day | Barry RichardPresident & CEO | PPurchase | +7.17K | $2.28 | +$16.4K | +1.0%714.7K after | |
| Sep 22, 2025 (view filing) | Sep 18-19 | 4 days | Barry RichardPresident & CEO | PPurchase | +237.9K | $2.25 | +$534.7K | +50.7%707.5K after | 4 lots |
| Dec 3, 2024 (view filing) | Nov 29 | 4 days | Kupiec James WilliamChief Medical Officer | SSale | −4.00K | $3.87 | −$15.5K | −100.0%0 after | |
| Dec 3, 2024 (view filing) | Nov 29 | 4 days | Schoen EricChief Financial Officer | SSale | −2.00K | $3.82 | −$7.64K | −100.0%0 after | |
| Dec 3, 2024 (view filing) | Nov 29 | 4 days | Schoen EricChief Financial Officer | SSale | −59.8K | $3.86 | −$230.8K | −83.9%11.5K after | |
| Aug 24, 2023 (view filing) | Aug 23 | 1 day | Robertson SanfordDirector | PPurchase | +30.0K | $17.45 | +$523.5K | +3.5%886.9K after | |
| Aug 23, 2023 (view filing) | Aug 21-22 | 2 days | Barry RichardDirector | PPurchase | +18.5K | $16.67 | +$307.9K | +6.7%293.5K after | 2 lots |
| Mar 8, 2023 (view filing) | Mar 6-7 | 2 days | Barry RichardDirector | PPurchase | +88.8K | $25.81 | +$2.29M | +47.7%275.0K after | 2 lots |
| Aug 25, 2022 (view filing) | Aug 23 | 2 days | Barry RichardDirector | PPurchase | +36.2K | $23.79 | +$860.2K | +24.1%186.2K after | |
| Aug 24, 2022 (view filing) | Aug 23 | 1 day | Kupiec James WilliamChief Clinical Dev. Officer | PPurchase | +2.50K | $24.44 | +$61.1K | New position2.50K after | |
| Aug 16, 2022 (view filing) | Aug 12 | 4 days | Schoen EricChief Financial Officer | PPurchase | +2.50K | $19.95 | +$49.9K | +14.5%19.8K after | |
| Aug 16, 2022 (view filing) | Aug 12 | 4 days | Robertson SanfordDirector | PPurchase | +100.0K | $20.69 | +$2.07M | +10.8%1.02M after |